Update on Traumakine drug substance manufacturing
Faron Pharmaceuticals Oy Update on Traumakine drug substance manufacturing - Faron contests termination of the agreement and files for arbitration - Proceedings funded by a third party on a non-recourse basis Company announcement, 30 December 2019 at 11.30 am (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) ("Faron" or the "Company"), the clinical stage biopharmaceutical company, announces that, further to the update on Traumakine® drug substance ("API") manufacturing announced on